Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351133 | 0.95 | KDM4E (0.57) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3889042 | 0.93 | KDM4E (0.55) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| SCHEMBL9539267 | 0.91 | KDM4E (0.53) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| Acetic Acid SCHEMBL237340 | 0.90 | SMN1; SMN2 (0.55) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| SCHEMBL2211080 | 0.87 | SLC6A2 (0.52) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| SCHEMBL2212225 | 0.87 | KDM4E (0.50) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| SCHEMBL583541 | 0.85 | TAAR1 (0.64) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| SCHEMBL6529683 | 0.83 | HTT (0.49) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| Water SCHEMBL8366271 | 0.82 | TAAR1 (0.61) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 | |
| Iodide SCHEMBL5092148 | 0.82 | TAAR1 (0.61) | KDM4EPOLBSLC6A2TAAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710464-A | Silicon oxide dielectric layer chemical mechanical polishing solution with low surface roughness | 博力思(天津)电子科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| US-12122874-B2 | Catalysts for ring opening polymerization | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-22 | — | — | US | disclosed |
| CN-115710464-A | Silicon oxide dielectric layer chemical mechanical polishing solution with low surface roughness | 博力思(天津)电子科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220112334-A1 | IMPROVED CATALYSTS FOR RING OPENING POLYMERIZATION | NATIONAL SCIENCE FOUNDATION | 2022-04-14 | — | — | US | disclosed |
| CN-109096128-B | Preparation method of aminopolyethylene glycol propionic acid | 江苏金斯瑞生物科技有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3006437-B1 | (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| WO-2020028332-A1 | IMPROVED CATALYSTS FOR RING OPENING POLYMERIZATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-2617812-B1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | UNIV TOKYO (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-3009426-B1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMA CO LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| WO-2008062006-A1 | COMPOSITION FOR REPELLING AND DETERRING VERMIN | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| US-7354942-B2 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
| EP-1689713-A1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Merck & Co., Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051914-A1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| EP-0214665-A2 | Derivatives of benzoine, process for their preparation and photocurable compositions containing these derivatives | Wacker-Chemie GmbH (DE) | 1987-03-18 | — | — | EP | disclosed |
| US-4353787-A | COATINGS, ADHESIVES, CASTINGS, REINFORCED COMPOSITES | SCOTT BADER COMPANY LIMITED (GB) | 1982-10-12 | — | — | US | disclosed |
| US-4226969-A | AMINE HARDENER, AMINOALCOHOL | ALLIED PRODUCTS CORPORATION (US) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | KDM4E 1371/4885POLB 3715/4885SLC6A2 732/4885 |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | KDM4E 2703/4885POLB 1864/4885SLC6A2 4502/4885 |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | BACE1, BACE2, APP | KDM4E 499/4885POLB 1669/4885SLC6A2 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.